ROCHE I/ CH0012032113 /
2024-07-26 5:30:46 PM | Chg. +7.00 | Volume | Bid8:54:19 PM | Ask8:54:19 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
312.00CHF | +2.30% | 45,986 Turnover: 14.27 mill. |
-Bid Size: 4 | -Ask Size: 20 | 264.73 bill.CHF | 3.04% | 21.67 |
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-14
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
04-03
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
04-02
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
03-14
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
02-26
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
01-03
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire
01-03
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
2023-12-29
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
GlobeNewswire
2023-12-14
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibo...